High Prevalence of Chronic Diseases and R&D in Positron Emission Tomography/Computed Tomography to Augment Growth of Molecular Imaging Market
Molecular imaging is an
emerging area of modern medical imaging, which focuses on labeling cells with
fluorescent or reflective molecules which are then observed under a microscope.
This is unlike traditional methods of obtaining molecular information from
frozen tissue samples, like biopsy. For one thing, molecular imaging does not
require any special tools; images can be obtained just by using ordinary
equipment like a digital camera and a fluorescence microscope for specimens
that are sufficiently small. The fluorescent or colored dyes used in the
analysis process emit wavelengths of green or yellow, which are detected by an
optical reader.
Market
Dynamics
High prevalence of
chronic diseases is expected to propel growth of the molecular imaging market.
For instance, according to the American Cancer Society, in 2019,
there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880
cancer deaths in the U.S. Moreover, successful
radiolabeling of imaging products is also expected to aid in growth of the
market. For instance, in January 2021, ARTMS Inc. and Isotopia MolecularImaging
announced the successful radiolabeling of Isotopia’s prostate cancer imaging
kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga)
using ARTMS’ proprietary Quantum Irradiation System solid target system.
R&D
in positron emission tomography/computed tomography is expected to offer
lucrative growth opportunities for players in the molecular
imaging market. For instance, in May
2020, Blue Earth Diagnostics, a Bracco company focused on molecular imaging
diagnostics, announced results from early clinical experience in Germany with
positron emission tomography/computed tomography (PET/CT) imaging using
rhPSMA-7.3 (18F), a radiohybrid Prostate Specific Membrane Antigen-targeted
compound.
The
global molecular imaging market is witnessing several M&A activities. For instance, in January 2021, Smart Breast
Corporation, a privately held company focused on breast cancer screening and
detection, acquired molecular breast imaging assets from Dilon Technologies for
an undisclosed amount.
Competitive
Analysis
Major players operating
in the global molecular imaging market include, Carestream Health, Fujifilm
Holdings Corporation, GE Healthcare, Hitachi Ltd, Hologic, Inc., Siemens AG,
Philips Healthcare, Samsung Medison, NorthStar Medical Radioisotopes, LLC, Shimadzu
Corporation, Isotopia
MolecularImaging, and Toshiba Medical Systems Corporation.
Major players operating
in the global molecular imaging market are focused on adopting various
strategies to enhance their market share. For instance, in June 2019, NorthStar
Medical Radioisotopes, LLC presented domestic Mo-99 production, expansion plans
and use of the RadioGenix System (technetium 99m generator) at the Society of
Nuclear Medicine and Molecular Imaging Annual Meeting.

Comments
Post a Comment